Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies

Chemico-Biological Interactions

Volumn 170, Issue 3, 2007, Pages 162-176

  Drozak, Jakub ^a   Kozlowski, Marcin ^a   Doroszewska, Renata ^a   Pera, Lukasz ^a   Derlacz, Rafal ^a   Jarzyna, Robert ^a   Bryla, Jadwiga ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Gluconeogenesis; Hepatocytes; Mitochondria; Renal tubules; Selegiline

Indexed keywords

ALANINE; ALLOXAN; AMPHETAMINE; DIHYDROXYACETONE; DRUG METABOLITE; GLUCOSE; GLYCEROL; METHAMPHETAMINE; NORSERTRALINE; OCTANOIC ACID; SELEGILINE; SELEGILINE N OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG MECHANISM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY TUBULE; LIVER CELL; MALE; MITOCHONDRION; NONHUMAN; OXYGEN CONSUMPTION; RABBIT;

ADENOSINE TRIPHOSPHATE; ANIMALS; BODY WEIGHT; CELL SEPARATION; CELLS, CULTURED; GLUCOSE; HEPATOCYTES; KIDNEY CORTEX; KIDNEY TUBULES; MALE; MITOCHONDRIA; MOLECULAR STRUCTURE; OXYGEN; RABBITS; SELEGILINE; SUPEROXIDES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 36049000929     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.07.013     Document Type: Article

References (68)

1. Knoll J., and Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5 (1972) 393-408
2. Youdim M.B., and Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25 (2004) 243-250
3. Riederer P., Lachenmayer L., and Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 11 (2004) 2033-2043
4. Youdim M.B., and Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 147 (2006) S287-S296
5. Foley P., Gerlach M., Youdim M.B.H., and Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders. Parkinsonism Relat. Disord. 6 (2000) 25-47
6. Magyar K., Palfi M., Tabi T., Kalasz H., Szende B., and Szoko E. Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem. 11 (2004) 2017-2031
7. Am O.B., Amit T., and Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355 (2004) 169-172
8. Tatton W.G., Chalmers-Redman R.M., Ju W.J., Mammen M., Carlile G.W., Pong A.W., and Tatton N.A. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301 (2002) 753-764
9. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. B.M.J. 311 (1995) 602-607
10. Gallagher I.M., Clow A., and Glover V. Long-term administration of (-)-deprenyl increases mortality in male Wistar rats. J. Neural Transm. Suppl. 52 (1998) 315-320
11. Shoulson I., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. 51 (2002) 604-612
12. Rowland M.J., Bransome E.D., and Hendry L.B. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted?. J. Clin. Pharmacol. 34 (1994) 80-85
13. Parvez H., Ismahan G., Parvez S., and Youdim M.B. Regulation of central and peripheral carbohydrate reserves after selective inhibition of enzyme monoamine oxidase: comparison between fed and starved rats. J. Pharmacol. 12 (1981) 123-133
14. Gerich J.E., Meyer C., Woerle H.J., and Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24 (2001) 382-391
15. Usatenko M.S. Hormonal regulation of phosphoenolpyruvate carboxykinase activity in liver and kidney of adult animals and formation of this enzyme in developing rabbit liver. Biochem. Med. 3 (1970) 298-310
16. Zaleski J., and Bryla J. Effect of alloxan-diabetes on gluconeogenesis and ureogenesis in isolated rabbit liver cells. Biochem. J. 176 (1978) 563-568
17. Loscher W., and Lehmann H. Anticonvulsant efficacy of l-deprenyl (selegiline) during chronic treatment in mice: continuous versus discontinuous administration. Neuropharmacology 37 (1998) 1587-1593
18. Youdim M.B., Gross A., Finberg J.P., and Rasagiline. [N-Propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132 (2001) 500-506
19. Cymerman Craig J., and Purushothaman K.K. An improved preparation of tertiary amine N-oxides. J. Org. Chem. 35 (1970) 1721-1722
20. Williamson J.R., Kreisberg R.A., and Felts P.W. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc. Natl. Acad. Sci. U.S.A. 56 (1966) 247-254
21. Jarzyna R., Kiersztan A., Lisowa O., and Bryla J. The inhibition of gluconeogenesis by chloroquine contributes to its hypoglycaemic action. Eur. J. Pharmacol. 428 (2001) 381-388
22. Krebs H.A., Cornell N.W., Lund P., and Hems R. Isolated liver cells as experimental material. In: Lundquist F., Tygstrup N., and Thysen J.H. (Eds). Regulation of Hepatic Metabolism (1974), Munksgaard, Copenhagen 726-750
23. Harris E.J., Tate C., Manger J.R., and Bangham J.A. The effects of colloids on the appearance and substrate permeability of rat liver mitochondria. J. Bioenerg. 2 (1971) 221-232
24. Zaleski J., Zablocki K., and Bryla J. Short-term effect of glucagon on gluconeogenesis and pyruvate kinase in rabbit hepatocytes. Int. J. Biochem. 14 (1982) 733-739 14
25. Ubeaud G., Schiller C.D., Hurbin F., Jaeck D., and Coassolo P. Estimation of flavin-containing monooxygenase activity in intact hepatocyte monolayers of rat, hamster, rabbit, dog and human by using N-oxidation of benzydamine. Eur. J. Pharm. Sci. 8 (1999) 255-260
26. Turpeinen M., Nieminen R., Juntunen T., Taavitsainen P., Raunio H., and Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab. Dispos. 32 (2004) 626-631
27. Bryla J., Harris E.J., and Plumb J.A. The stimulatory effect of glucagon and dibutyryl cyclic AMP on ureogenesis and gluconeogenesis in relation to the mitochondrial ATP content. FEBS Lett. 80 (1977) 443-448 80
28. Derlacz R., Kiersztan A., Winiarska K., Jagielski A.K., Drozak J., Konior A., Popławski P., Chodnicka K., and Bryła J. The effect of ethanol on glucose and glutamine synthesis in rabbit renal tubules. Alcohol Alcohol. 39 (2004) 93-100
29. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
30. Katagi M., Tatsuno M., Miki A., Nishikawa M., Nakajima K., and Tsuchihashi H. Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 759 (2001) 125-133
31. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1984), Verlag Chemie GmbH, Weinheim, Deerfield Beach, Florida-Basel
32. Teerlink T., Hennekes M., Bussemaker J., and Groeneveld J. Simultaneous determination of creatine compounds and adenine nucleotides in myocardial tissue by high-performance liquid chromatography. Anal. Biochem. 214 (1993) 278-283
33. Da Fonseca-Wollheim F., and Heinze K.G. Which is the appropriate coenzyme for the measurement of ammonia with glutamate dehydrogenase?. Eur. J. Clin. Chem. Clin. Biochem. 30 (1992) 537-540
34. Michalik M., Biedermann I., Lietz T., and Bryla J. Recovery of impaired gluconeogenesis in kidney-cortex tubules of gentamicin-treated rabbits. Pharmacol. Res. 23 (1991) 259-269
35. Gardner R.S. A sensitive colorimetric assay for mitochondrial alpha-glycerophosphate dehydrogenase. Anal. Biochem. 56 (1974) 272-276
36. Barja G. Kinetic measurement of mitochondrial oxygen radical production. In: Yu B.P. (Ed). Methods in Aging Research (1999), CRC Press, Boca Raton 533-548
37. Lietz T., Rybka J., and Bryla J. Fatty acids and glycerol or lactate are required to induce gluconeogenesis from alanine in isolated rabbit renal cortical tubules. Amino Acids 16 (1999) 41-58
38. Szende B., Bokonyi G., Bocsi J., Keri G., Timar F., and Magyar K. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J. Neural Transm. 108 (2001) 25-33
39. Jenei V., Zor K., Magyar K., and Jakus J. Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl. J. Neural Transm. 112 (2005) 1433-1445
40. Hidestrand M., Oscarson M., Salonen J.S., Nyman L., Pelkonen O., Turpeinen M., and Ingelman-Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 29 (2001) 1480-1484
41. Tsutsumi H., Katagi M., Nishikawa M., Tsuchihashi H., Kasuya F., and Igarashi K. In vitro confirmation of selegiline N-oxidation by flavin-containing monooxygenase in rat microsome using LC-ESI MS. Biol. Pharm. Bull. 27 (2004) 1572-1575
42. Brown L.J., Koza R.A., Everett C., Reitman M.L., Marshall L., Fahien L.A., Kozak L.P., and MacDonald M.J. Normal thyroid thermogenesis but reduced viability and adiposity in mice lacking the mitochondrial glycerol phosphate dehydrogenase. J. Biol. Chem. 277 (2002) 32892-32898
43. Thiffault C., Quirion R., and Poirier J. The effect of l-deprenyl, d-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Brain Res. Mol. Brain Res. 49 (1997) 127-136
44. Clarke A., Brewer F., Johnson E.S., Mallard N., Hartig F., Taylor S., and Corn T.H. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Transm. 110 (2003) 1241-1255
45. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet. 33 (1997) 91-102
46. Patkar A.A., Pae C.U., and Masand P.S. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 11 (2006) 363-375
47. Anttila M., Sotaniemi E.A., Pelkonen O., and Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin. Pharmacol. Ther. 77 (2005) 54-62
48. EMSAM Package Insert (2006), Bristol-Myers Squibb Company, Princeton, NJ
49. Melega W.P., Cho A.K., Schmitz D., Kuczenski R., and Segal D.S. l-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J. Pharmacol. Exp. Ther. 288 (1999) 752-758
50. Kiersztan A., Lukasinska I., Baranska A., Lebiedzinska M., Nagalski A., Derlacz R.A., and Bryla J. Differential effects of selenium compounds on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies. J. Inorg. Biochem. 101 (2007) 493-505
51. Cam M.C., Pederson R.A., Brownsey R.W., and McNeill J.H. Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia 36 (1993) 218-224
52. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., and Kahn C.R. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol. Cell. Biochem. 153 (1995) 217-231
53. Goldfine A.B., Patti M.E., Zuberi L., Goldstein B.J., LeBlanc R., Landaker E.J., Jiang Z.Y., Willsky G.R., and Kahn C.R. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metab. Clin. Exp. 49 (2000) 400-410
54. Kamada T., Chow T., Hiroi T., Imaoka S., Morimoto K., Ohde H., and Funae Y. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab. Pharmacokinet. 17 (2002) 199-206
55. Salonen J.S., Nyman L., Boobis A.R., Edwards R.J., Watts P., Lake B.G., Price R.J., Renwick A.B., Gomez-Lechon M.J., Castell J.V., Ingelman-Sundberg M., Hidestrand M., Guillouzo A., Corcos L., Goldfarb P.S., Lewis D.F., Taavitsainen P., and Pelkonen O. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos. 31 (2003) 1093-1102
56. Kiersztan A., Modzelewska A., Jarzyna R., Jagielska E., and Bryla J. Inhibition of gluconeogenesis by vanadium and metformin in kidney-cortex tubules isolated from control and diabetic rabbits. Biochem. Pharmacol. 63 (2002) 1371-1382
57. Kiersztan A., Winiarska K., Drozak J., Przedlacka M., Wegrzynowicz M., Fraczyk T., and Bryla J. Differential effects of vanadium, tungsten and molybdenum on inhibition of glucose formation in renal tubules and hepatocytes of control and diabetic rabbits: beneficial action of melatonin and N-acetylcysteine. Mol. Cell. Biochem. 261 (2004) 9-21
58. Masubuchi Y., Yamada S., and Horie T. Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 292 (2000) 982-987
59. Acco A., Comar J.F., and Bracht A. Metabolic effects of propofol in the isolated perfused rat liver. Basic Clin. Pharmacol. Toxicol. 95 (2004) 166-174
60. Drozak J., Doroszewska R., Chodnicka K., Winiarska K., and Bryla J. Contribution of l-3,4-dihydroxyphenylalanine metabolism to the inhibition of gluconeogenesis in rabbit kidney-cortex tubules. Int. J. Biochem. Cell. Biol. 37 (2005) 1269-1280
61. Du X.L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., Wu J., and Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12222-12226
62. Lambert A.J., and Brand M.D. Superoxide production by NADH:ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. Biochem. J. 382 (2004) 511-517
63. Lietz T., and Bryla J. Glycerol and lactate induce reciprocal changes in glucose formation and glutamine production in isolated rabbit kidney-cortex tubules incubated with aspartate. Arch. Biochem. Biophys. 321 (1995) 501-509
64. Bischof M.G., Krssak M., Krebs M., Bernroider E., Stingl H., Waldhausl W., and Roden M. Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes 50 (2001) 392-398
65. Adrogue H.J. Glucose homeostasis and the kidney. Kidney Int. 42 (1992) 1266-1282
66. Carlile G.W., Chalmers-Redman R.M., Tatton N.A., Pong A., Borden K.E., and Tatton W.G. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimmer. Mol. Pharmacol. 57 (2000) 2-12
67. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., and Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79 (2005) 172-179
68. Toronyi E., Hamar J., Magyar K., and Szende B. Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. Med. Sci. Monit. 8 (2002) BR65-BR68